The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia
Introduction: The prognosis of chronic myeloid leukemia (CML) patients has been dramatically improved with the introduction of imatinib (IM), the first tyrosine kinase inhibitor (TKI). TKI resistance is a serious problem in IM-based therapy. The human S-phase kinase-associated protein 2 (<i>SK...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Genes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4425/13/6/948 |
| _version_ | 1797487171161030656 |
|---|---|
| author | Hossam Hodeib Dina Abd EL Hai Mohamed A. Tawfik Alzahraa A. Allam Ahmed F. Selim Mohamed E. Sarhan Amal Selim Nesreen M. Sabry Wael Mansour Amira Youssef |
| author_facet | Hossam Hodeib Dina Abd EL Hai Mohamed A. Tawfik Alzahraa A. Allam Ahmed F. Selim Mohamed E. Sarhan Amal Selim Nesreen M. Sabry Wael Mansour Amira Youssef |
| author_sort | Hossam Hodeib |
| collection | DOAJ |
| description | Introduction: The prognosis of chronic myeloid leukemia (CML) patients has been dramatically improved with the introduction of imatinib (IM), the first tyrosine kinase inhibitor (TKI). TKI resistance is a serious problem in IM-based therapy. The human S-phase kinase-associated protein 2 (<i>SKP2</i>) gene may play an essential role in the genesis and progression of CML. Aim of the study: We try to explore the diagnostic/prognostic impact of <i>SKP2</i> gene expression to predict treatment response in first-line IM-treated CML patients at an early response stage. Patients and methods: The gene expression and protein levels of SKP2 were determined using quantitative RT-PCR and ELISA in 100 newly diagnosed CML patients and 100 healthy subjects. Results: <i>SKP2</i> gene expression and SKP2 protein levels were significantly upregulated in CML patients compared to the control group. The receiver operating characteristic (ROC) analysis for the <i>SKP2</i> gene expression level, which that differentiated the CML patients from the healthy subjects, yielded a sensitivity of 86.0% and a specificity of 82.0%, with an area under the curve (AUC) of 0.958 (<i>p</i> < 0.001). The ROC analysis for the <i>SKP2</i> gene expression level, which differentiated optimally from the warning/failure responses, yielded a sensitivity of 70.59% and a specificity of 71.21%, with an AUC of 0.815 (<i>p</i> < 0.001). Conclusion: The <i>SKP2</i> gene could be an additional diagnostic and an independent prognostic marker for predicting treatment responses in first-line IM-treated CML patients at an early time point (3 months). |
| first_indexed | 2024-03-09T23:43:47Z |
| format | Article |
| id | doaj.art-58d632cdb07b4bb397d7a87bbaa44eb8 |
| institution | Directory Open Access Journal |
| issn | 2073-4425 |
| language | English |
| last_indexed | 2024-03-09T23:43:47Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Genes |
| spelling | doaj.art-58d632cdb07b4bb397d7a87bbaa44eb82023-11-23T16:46:45ZengMDPI AGGenes2073-44252022-05-0113694810.3390/genes13060948The Impact of SKP2 Gene Expression in Chronic Myeloid LeukemiaHossam Hodeib0Dina Abd EL Hai1Mohamed A. Tawfik2Alzahraa A. Allam3Ahmed F. Selim4Mohamed E. Sarhan5Amal Selim6Nesreen M. Sabry7Wael Mansour8Amira Youssef9Clinical Pathology Department, Tanta University, Tanta 31527, EgyptClinical Pathology Department, Tanta University, Tanta 31527, EgyptInternal Medicine Department, Tanta University, Tanta 31527, EgyptInternal Medicine Department, Tanta University, Tanta 31527, EgyptInternal Medicine Department, Tanta University, Tanta 31527, EgyptInternal Medicine Department, Tanta University, Tanta 31527, EgyptInternal Medicine Department, Tanta University, Tanta 31527, EgyptClinical Oncology Department, Tanta University, Tanta 31527, EgyptClinical Oncology Department, Tanta University, Tanta 31527, EgyptClinical Pathology Department, Tanta University, Tanta 31527, EgyptIntroduction: The prognosis of chronic myeloid leukemia (CML) patients has been dramatically improved with the introduction of imatinib (IM), the first tyrosine kinase inhibitor (TKI). TKI resistance is a serious problem in IM-based therapy. The human S-phase kinase-associated protein 2 (<i>SKP2</i>) gene may play an essential role in the genesis and progression of CML. Aim of the study: We try to explore the diagnostic/prognostic impact of <i>SKP2</i> gene expression to predict treatment response in first-line IM-treated CML patients at an early response stage. Patients and methods: The gene expression and protein levels of SKP2 were determined using quantitative RT-PCR and ELISA in 100 newly diagnosed CML patients and 100 healthy subjects. Results: <i>SKP2</i> gene expression and SKP2 protein levels were significantly upregulated in CML patients compared to the control group. The receiver operating characteristic (ROC) analysis for the <i>SKP2</i> gene expression level, which that differentiated the CML patients from the healthy subjects, yielded a sensitivity of 86.0% and a specificity of 82.0%, with an area under the curve (AUC) of 0.958 (<i>p</i> < 0.001). The ROC analysis for the <i>SKP2</i> gene expression level, which differentiated optimally from the warning/failure responses, yielded a sensitivity of 70.59% and a specificity of 71.21%, with an AUC of 0.815 (<i>p</i> < 0.001). Conclusion: The <i>SKP2</i> gene could be an additional diagnostic and an independent prognostic marker for predicting treatment responses in first-line IM-treated CML patients at an early time point (3 months).https://www.mdpi.com/2073-4425/13/6/948<i>SKP2</i> gene expressionimatinibtreatment responsechronic myeloid leukemia |
| spellingShingle | Hossam Hodeib Dina Abd EL Hai Mohamed A. Tawfik Alzahraa A. Allam Ahmed F. Selim Mohamed E. Sarhan Amal Selim Nesreen M. Sabry Wael Mansour Amira Youssef The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia Genes <i>SKP2</i> gene expression imatinib treatment response chronic myeloid leukemia |
| title | The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia |
| title_full | The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia |
| title_fullStr | The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia |
| title_full_unstemmed | The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia |
| title_short | The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia |
| title_sort | impact of skp2 gene expression in chronic myeloid leukemia |
| topic | <i>SKP2</i> gene expression imatinib treatment response chronic myeloid leukemia |
| url | https://www.mdpi.com/2073-4425/13/6/948 |
| work_keys_str_mv | AT hossamhodeib theimpactofskp2geneexpressioninchronicmyeloidleukemia AT dinaabdelhai theimpactofskp2geneexpressioninchronicmyeloidleukemia AT mohamedatawfik theimpactofskp2geneexpressioninchronicmyeloidleukemia AT alzahraaaallam theimpactofskp2geneexpressioninchronicmyeloidleukemia AT ahmedfselim theimpactofskp2geneexpressioninchronicmyeloidleukemia AT mohamedesarhan theimpactofskp2geneexpressioninchronicmyeloidleukemia AT amalselim theimpactofskp2geneexpressioninchronicmyeloidleukemia AT nesreenmsabry theimpactofskp2geneexpressioninchronicmyeloidleukemia AT waelmansour theimpactofskp2geneexpressioninchronicmyeloidleukemia AT amirayoussef theimpactofskp2geneexpressioninchronicmyeloidleukemia AT hossamhodeib impactofskp2geneexpressioninchronicmyeloidleukemia AT dinaabdelhai impactofskp2geneexpressioninchronicmyeloidleukemia AT mohamedatawfik impactofskp2geneexpressioninchronicmyeloidleukemia AT alzahraaaallam impactofskp2geneexpressioninchronicmyeloidleukemia AT ahmedfselim impactofskp2geneexpressioninchronicmyeloidleukemia AT mohamedesarhan impactofskp2geneexpressioninchronicmyeloidleukemia AT amalselim impactofskp2geneexpressioninchronicmyeloidleukemia AT nesreenmsabry impactofskp2geneexpressioninchronicmyeloidleukemia AT waelmansour impactofskp2geneexpressioninchronicmyeloidleukemia AT amirayoussef impactofskp2geneexpressioninchronicmyeloidleukemia |